Skip to content
Menu

Korsana Biosciences, Inc. KRSA

Full chart Compare
Set alert

Price alert · KRSA

All alert types
37.56 USD +2.11 (+5.95%)

Regular-session close

37.56 0.00 0.00%

After hours · Nov 20, 4:00 PM ET

34.51 Day range 39.41
7.56 52-week range 44.66
YTD
+322.50%
1 year
+277.87%

5D +6.77 (+21.02%)

32.503537.50MonTueWedThuFri38.97
Market cap
1.71B
EPS (ttm)
-16.14
Shares out
45.54M
Forward P/E
-10.71
YTD return
+322.50%
1-year return
+277.87%
50-day average
32.19
200-day average
23.51
Enterprise value
255.17M
Total cash
134.16M
Volume
265.24K
Avg volume
115.71K
Open
35.96
Previous close
35.45
Day's range
34.51 – 39.41
52-week range
7.56 – 44.66
Beta
1.84
Analysts
Strong Buy
Price target
44.00 (+17.1%)
Earnings date
Mar 29, 2027

Key statistics

Total debt
1.10M

Fundamental scorecard

4 of 25 checks passed on KRSA’s reported financials

ValueGrowthProfitabilityHealthDividend

4of 25 checks passed

  • Value 0 of 5
  • Growth 1 of 5
  • Profitability 0 of 5
  • Financial health 3 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
KRSA Revenue — quarterly 0
KRSA Net income — quarterly -46.42M
KRSA EPS — quarterly -3.19

Earnings

KRSA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Mar 29, 2027Dec 30, 2026-0.89———
Nov 5, 2026Sep 30, 2026-0.84695-3.19-2.34-276.65%
Aug 4, 2026Jun 30, 2026-3.45-0.41+3.04+88.12%
May 5, 2026Mar 31, 2026-2.66-2.660.000.00%
Mar 17, 2026Dec 31, 2025-2.66-1.75+0.91+34.21%
Nov 12, 2025Sep 30, 2025-121.80-0.30+121.50+99.75%

Upgrades / downgrades

KRSA analyst upgrades and downgrades
DateFirmActionFromTo
Nov 13, 2026Wells Fargoinit—Overweight
Oct 5, 2026Wedbushinit—Outperform
Sep 28, 2026Guggenheiminit—Buy
Sep 14, 2026Stifelinit—Buy
Sep 14, 2026TD Coweninit—Buy
Sep 11, 2026UBSinit—Buy

About Korsana Biosciences, Inc.

Korsana Biosciences, Inc. develops therapeutic antibodies for the treatment of neurodegenerative diseases. The company has developed Therapeutic Targeting (THETA), a blood-brain barrier-penetrant shuttle platform designed to enhance central nervous system exposure of investigational therapies and enable delivery of large therapeutic molecules across the blood-brain barrier into the central nervous system. The company advances a pipeline of THETA-enabled therapeutics with an initial focus on neurodegenerative disorders. Its lead product candidate is KRSA-028, an anti-amyloid beta antibody for the treatment of Alzheimer's disease, which combines the THETA platform with elements of anti-amyloid beta approaches and targets a clinically relevant form of amyloid beta designed to improve brain uptake while reducing effects on reticulocytes. The company is also advancing a pipeline of additional THETA-enabled therapies for other neurodegenerative diseases. Korsana Biosciences, Inc. was incorporated in 2024 and is based in Waltham, Massachusetts.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
korsana.com

News

Your note

Sign in to keep a note on KRSA — it syncs with the Stock Master app.

Insider holders

KRSA insider holders
InsiderRelationLatest transactionDateShares held
CHICKO RHONDA M. CPAChief Financial OfficerConversion of Exercise of derivative securityAug 13, 202625,018
GRAUL REGINA MARGARETChief Executive OfficerConversion of Exercise of derivative securityAug 13, 2026107,523
HECHT PETER MDirector and Beneficial Owner of more than 10% of a Class of SecurityConversion of Exercise of derivative securityJul 15, 2026910,312
HIGGINS MICHAEL JDirectorStock Award(Grant)Mar 24, 202530,740
SLATE PATH CAPITAL LPBeneficial Owner of more than 10% of a Class of SecuritySaleNov 20, 20240

Institution ownership

KRSA institution ownership
Holder% heldSharesValueReported
Fairmount Funds Management LLC19.99%9,103,729341.94MSep 29, 2026
TCG Crossover Management, LLC9.99%4,549,587170.88MSep 29, 2026
Venrock Adviser, LLC9.99%4,549,585170.88MSep 29, 2026
FMR, LLC7.03%3,201,135120.23MSep 29, 2026
JPMORGAN CHASE & CO5.90%2,687,943100.96MSep 29, 2026
FCPM III Services B.V.4.81%2,192,15582.34MSep 29, 2026

Fund ownership

KRSA fund ownership
Holder% heldSharesValueReported
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund1.79%813,16330.54MSep 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Growth Company K6 Fund0.50%226,5838.51MSep 29, 2026
Fidelity Mt. Vernon Street Trust-Fidelity Series Growth Company Fund0.45%205,4937.72MSep 29, 2026
Fidelity Select Portfolios-Select Health Care Portfolio0.29%131,5474.94MSep 29, 2026
Fidelity Advisor Series VII-Fidelity Advisor Health Care Fund0.14%65,3642.46MSep 29, 2026
Fidelity Select Portfolios-Select Biotechnology Portfolio0.11%51,5181.94MSep 29, 2026